2024-09-20 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops and commercializes medicines for the treatment of life-threatening diseases.

**1. Performance vs. S&P 500:**

Gilead Sciences (GILD) has underperformed the S&P 500 (VOO) significantly. While VOO has seen a cumulative return of 128.99%, GILD has experienced a -12.93% cumulative return. This difference represents a relative divergence of -141.92, indicating that GILD has been underperforming compared to the broader market.

**2. Recent Price Movement:**

* Closing price: $83.89
* 5-day moving average: $83.23
* 20-day moving average: $79.64
* 60-day moving average: $74.86

The recent price movement suggests that GILD is experiencing an upward trend in the short term, with the current price above all three moving averages.

**3. Technical Indicators:**

* RSI: 76.84 -  This indicates that the stock is currently in overbought territory.
* PPO: 0.35 -  This suggests a strong momentum in the stock price.
* Delta_Previous_Relative_Divergence: 4.28 - This indicates a recent positive shift in the relative divergence trend, suggesting potential upward movement.
* Expected_Return: 17.98% - This suggests a potential 5-year return for current investments.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for the quarter ending August 8th, 2024 showed an EPS of 1.29 and revenue of $6.95 billion. This exceeded analysts' expectations of $0.84 EPS and $6.60 billion in revenue.  

**5. Summary:**

Gilead Sciences (GILD) has underperformed the broader market significantly. However, recent price movements and technical indicators suggest potential upside in the short term. The stock is currently considered overbought based on the RSI, but the positive PPO and delta_previous_relative_divergence indicate a potential for further growth. The company's recent earnings report exceeded expectations, potentially supporting the positive technical outlook.

**6. Report:**

Gilead Sciences Inc. (GILD) has had a difficult time keeping up with the market, significantly underperforming the S&P 500 (VOO) in recent years. While the company has faced challenges in the past, recent positive momentum and strong earnings suggest a potential turnaround. Despite the stock being considered overbought, the current price action remains bullish, with the PPO and Delta_Previous_Relative_Divergence indicating a potential for further growth. The company's strong Q2 2024 earnings, exceeding analysts' expectations, also points towards a positive future. With the stock showing signs of a resurgence and potential for future growth, investors may want to consider Gilead Sciences as a potential addition to their portfolio. 
